Cardiac fibrosis
Open accessThe DOI matches its Crossref record; 612 of the 615 references it cites were found in a registry or an index.
Abstract
Myocardial fibrosis, the expansion of the cardiac interstitium through deposition of extracellular matrix proteins, is a common pathophysiologic companion of many different myocardial conditions. Fibrosis may reflect activation of reparative or maladaptive processes. Activated fibroblasts and myofibroblasts are the central cellular effectors in cardiac fibrosis, serving as the main source of matrix proteins. Immune cells, vascular cells and cardiomyocytes may also acquire a fibrogenic phenotype under conditions of stress, activating fibroblast populations. Fibrogenic growth factors (such as transforming growth factor-β and platelet-derived growth factors), cytokines [including tumour necrosis factor-α, interleukin (IL)-1, IL-6, IL-10, and IL-4], and neurohumoral pathways trigger fibrogenic signalling cascades through binding to surface receptors, and activation of downstream signalling cascades. In addition, matricellular macromolecules are deposited in the remodelling myocardium and regulate matrix assembly, while modulating signal transduction cascades and protease or growth factor activity. Cardiac fibroblasts can also sense mechanical stress through mechanosensitive receptors, ion channels and integrins, activating intracellular fibrogenic cascades that contribute to fibrosis in response to pressure overload. Although subpopulations of fibroblast-like cells may exert important protective actions in both reparative and interstitial/perivascular fibrosis, ultimately fibrotic changes perturb systolic and diastolic function, and may play an important role in the pathogenesis of arrhythmias. This review article discusses the molecular mechanisms involved in the pathogenesis of cardiac fibrosis in various myocardial diseases, including myocardial infarction, heart failure with reduced or preserved ejection fraction, genetic cardiomyopathies, and diabetic heart disease. Development of fibrosis-targeting therapies for patients with myocardial diseases will require not only understanding of the functional pluralism of cardiac fibroblasts and dissection of the molecular basis for fibrotic remodelling, but also appreciation of the pathophysiologic heterogeneity of fibrosis-associated myocardial disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inflammation and tissue fibrosis co-exist and are causally linked to organ dysfunction1,2.”
From Targeting immune–fibroblast cell communication in heart failure (2024) · cites this paper as [2]
In the citing paper
“Among stromal cell types, fibroblasts are of particular interest given their role in tissue fibrosis, arrhythmias, and heart failure 16,29,30 .”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [30]
Citations
Cites
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495 · cited 1×
“Fibrosis is an important cause of organ dysfunction in many different diseases, including interstitial lung diseases, liver cirrhosis, progressive systemic sclerosis, and diabetic nephropathy.(1)”
BackgroundMyofibroblasts and mechano-regulation of connective tissue remodelling
Tomasek, J. J., Gabbiani, G., Hinz, B., Chaponnier, C., & Brown, R. A. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm809 · Cited by 4,290
A Novel Paradigm for Heart Failure With Preserved Ejection Fraction
Paulus, W. J., & Tschöpe, C. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.092 · Cited by 3,564
Obesity and the risk of heart failure
Kenchaiah, S., Evans, J. C., Levy, D., Wilson, P. W. F., Benjamin, E. J., Larson, M. G., Kannel, W. B., & Vasan, R. S. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020245 · Cited by 3,093
Ignotz, R. A., & Massagué, J. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35666-1 · Cited by 2,492
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., et al. (2008) · Nature · doi:10.1038/nature07511 · Cited by 2,349
Desmoulière, A., Geinoz, A., Gabbiani, F., & Gabbiani, G. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.103 · Cited by 2,243
The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis
Prabhu, S. D., & Frangogiannis, N. G. (2016) · Circulation Research · doi:10.1161/circresaha.116.303577 · Cited by 2,224
Self-citationEndothelial-to-mesenchymal transition contributes to cardiac fibrosis
Zeisberg, E. M., Tarnavski, O., Zeisberg, M., Dorfman, A. L., McMullen, J. R., Gustafsson, E., Chandraker, A., Yuan, X., Pu, W. T., Roberts, A. B., et al. (2007) · Nature Medicine · doi:10.1038/nm1613 · Cited by 2,222 · cited 2×
“The antifibrotic effects were attributed to blockade of TGF-b signalling and were associated with attenuated endothelial to mesenchymal transition.(22,247) Moreover, gain-of-function studies have”
BackgroundHinz, B., Phan, S. H., Thannickal, V. J., Galli, A., Bochaton-Piallat, M.-L., & Gabbiani, G. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070112 · Cited by 2,068
Cited by
Cellular mechanotransduction in health and diseases: from molecular mechanism to therapeutic targets
Di, X., Gao, X., Peng, L., Ai, J., Jin, X., Qi, S., Li, H., Wang, K., & Luo, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01501-9 · Cited by 622
“Cardiac fibroblast can sense mechanical cues through mechanosensitive receptors, and channels, hence promoting intracellular fibrogenic signaling.(634) Previous studies demonstrated that cyclic stretch promotes fibroblast activation and FMT.”
BackgroundMacrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets
Chen, R., Zhang, H., Tang, B., Luo, Y., Yang, Y., Zhong, X., Chen, S., Xu, X., Huang, S., & Liu, C. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01840-1 · Cited by 349
Antar, S. A., Ashour, N. A., Marawan, M. E., & Al-Karmalawy, A. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044004 · Cited by 366
“Cardiac fibrosis is an aberrant thickening of the heart valves caused by unsuitable fibroblast proliferation, but it is more frequently used to describe the excessive deposition of ECM in the cardiac muscle, as described in Figure 12 [123].”
BackgroundGoette, A., Corradi, D., Dobrev, D., Aguinaga, L., Cabrera, J.-A., Chugh, S. S., de Groot, J. R., Soulat-Dufour, L., Fenelon, G., Hatem, S. N., et al. (2024) · Europace · doi:10.1093/europace/euae204 · Cited by 310
Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets
Guan, F., Wang, R., Yi, Z., Luo, P., Liu, W., Xie, Y., Liu, Z., Xia, Z., Zhang, H., & Cheng, Q. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02124-y · Cited by 371
Transforming growth factor-β in myocardial disease
Frangogiannis, N. G. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00646-w · Cited by 344
Self-citationTargeting immune–fibroblast cell communication in heart failure
Amrute, J. M., Luo, X., Penna, V., Yang, S., Yamawaki, T., Hayat, S., Bredemeyer, A., Jung, I.-H., Kadyrov, F. F., Heo, G. S., et al. (2024) · Nature · doi:10.1038/s41586-024-08008-5 · Cited by 339
The Pathogenesis of Cardiac Fibrosis: A Review of Recent Progress
Maruyama, K., & Imanaka-Yoshida, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052617 · Cited by 205
Fibroblasts: Immunomodulatory factors in refractory diabetic wound healing
Liu, Y., Liu, Y., He, W., Mu, X., Wu, X., Deng, J., & Nie, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.918223 · Cited by 163
“Furthermore, studies have revealed that fibrous tissue remodeling is associated with increased expressions of MMP and humora l factors such as TGF, Ang II , endothelin-1 (ET-1), and TNF-a (29, 62).”
BackgroundPhytochemistry and cardiovascular protective effects of Huang‐Qi (Astragali Radix)
Su, H., Shaker, S., Kuang, Y., Zhang, M., Ye, M., & Qiao, X. (2021) · Medicinal Research Reviews · doi:10.1002/med.21785 · Cited by 170
Low-Grade Chronic Inflammation: a Shared Mechanism for Chronic Diseases
Cifuentes, M., Verdejo, H., Castro, P., Corvalán, A. H., Ferreccio, C., Quest, A. F. G., Kogan, M. J., & Lavandero, S. (2024) · Physiology · doi:10.1152/physiol.00021.2024 · Cited by 199
Cardiac fibroblasts and mechanosensation in heart development, health and disease
Pesce, M., Duda, G. N., Forte, G., Girão, H., Raya, Á., Roca‐Cusachs, P., Sluijter, J. P. G., Tschöpe, C., & Linthout, S. V. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00799-2 · Cited by 166
A Cardiac‐Targeted Nanozyme Interrupts the Inflammation‐Free Radical Cycle in Myocardial Infarction
Liu, X., Chen, B., Chen, J., Wang, X., Dai, X., Li, Y., Zhou, H., Wu, L., Liu, Z., & Yang, Y. P. (2023) · Advanced Materials · doi:10.1002/adma.202308477 · Cited by 162
Pugliese, N. R., Pellicori, P., Filidei, F., De Biase, N., Maffia, P., Guzik, T. J., Masi, S., Taddei, S., & Cleland, J. G. F. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvac133 · Cited by 144
Gao, L., Qiu, F., Cao, H., Li, H., Dai, G., Ma, T., Gong, Y., Luo, W., Zhu, D., Qiu, Z., et al. (2023) · Theranostics · doi:10.7150/thno.73568 · Cited by 154
Zhuang, T., Chen, M., Wu, R.-X., Wang, J., Hu, X.-D., Meng, T., Wu, A.-H., Li, Y., Yang, Y., Lei, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46357-x · Cited by 157
Bhattacharya, M., & Ramachandran, P. (2023) · Nature Immunology · doi:10.1038/s41590-023-01551-9 · Cited by 148
Tuleta, I., & Frangogiannis, N. G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113904 · Cited by 150
Self-citationThe role of matrix metalloproteinase 9 in fibrosis diseases and its molecular mechanisms
Wang, Y., Jiao, L., Qiang, C., Chen, C., Shen, Z., Ding, F., Lv, L., Zhu, T., Lu, Y., & Cui, X. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116116 · Cited by 144
Molecular Mechanisms of Obesity-Linked Cardiac Dysfunction: An Up-Date on Current Knowledge
Gutiérrez‐Cuevas, J., Sandoval-Rodriguez, A. S., Meza-Ríos, A., Monroy-Ramírez, H. C., Galicia‐Moreno, M., Garcia-Bañuelos, J. J., Santos, A., & Armendáriz‐Borunda, J. (2021) · Cells · doi:10.3390/cells10030629 · Cited by 140
Triglyceride-glucose index (TyG) as a novel biomarker in the era of cardiometabolic medicine
Арманович, А. А., Вачиковна, П. Н., Fogacci, F., Aghajanova, E., Jndoyan, Z., Patoulias, D., Sasso, L. L., Bernardi, M., Faggiano, A., Mohammadifard, N., et al. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132663 · Cited by 141
Cardiac Fibrosis in the Multi-Omics Era: Implications for Heart Failure
Ghazal, R., Wang, M., Liu, D., Tschumperlin, D. J., & Pereira, N. L. (2025) · Circulation Research · doi:10.1161/circresaha.124.325402 · Cited by 140
Lazzerini, P. E., Abbate, A., Boutjdir, M., & Capecchi, P. L. (2023) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2022.12.004 · Cited by 115
Single-cell transcriptomics for the assessment of cardiac disease
Miranda, A. M. A., Janbandhu, V., Maatz, H., Kanemaru, K., Cranley, J., Teichmann, S. A., Hübner, N., Schneider, M. D., Harvey, R. P., & Noseda, M. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00805-7 · Cited by 117
Inflammation in Metabolic Cardiomyopathy
Wenzl, F. A., Ambrosini, S., Mohammed, S. A., Kraler, S. C., Lüscher, T. F., Costantino, S., & Paneni, F. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.742178 · Cited by 122
Kruszewska, J., Cudnoch‐Jędrzejewska, A., & Czarzasta, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084195 · Cited by 126
“The epimysium is a sheath of connective tissue surrounding the entire muscle, whereas the perimysium surrounds groups of myocytes and the endomysium interconnects individual cells [76].”
BackgroundAkiyama, T., Yasuda, T., Uchihara, T., Yasuda‐Yoshihara, N., Tan, B. J. Y., Yonemura, A., Semba, T., Yamasaki, J., Komohara, Y., Ohnishi, K., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1890 · Cited by 116
Buja, L. M. (2022) · Cardiology in Review · doi:10.1097/crd.0000000000000440 · Cited by 120
Electrophysiological Consequences of Cardiac Fibrosis
Verheule, S., & Schotten, U. (2021) · Cells · doi:10.3390/cells10113220 · Cited by 120
“In the heart, both normal and excess fibrous tissue consist primarily of the fibrillar collagen types I and III [3].”
BackgroundCardiac Fibrosis in the Pressure Overloaded Left and Right Ventricle as a Therapeutic Target
Schimmel, K., Ichimura, K., Reddy, S., Haddad, F., & Spiekerkoetter, E. F. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.886553 · Cited by 108
“In addition, TGFβ1 can trigger non-canonical, SMAD-independent signaling, that is mediated by TGFβ-activated kinase 1 (TAK1), mitogen-activated protein kinases (MAPKs) and Rho A (76).”
BackgroundChen, G., Xu, H., Xu, T., Ding, W., Zhang, G., Hua, Y., Wu, Y., Han, X., Xie, L., Liu, B., et al. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154277 · Cited by 107
Reduction of Cardiac Fibrosis by Interference With YAP-Dependent Transactivation
Garoffolo, G., Casaburo, M., Amadeo, F., Salvi, M., Bernava, G., Piacentini, L., Chimenti, I., Zaccagnini, G., Milcovich, G., Zuccolo, E., et al. (2022) · Circulation Research · doi:10.1161/circresaha.121.319373 · Cited by 107
Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies
Di, X., Li, Y., Wei, J., Li, T., & Liao, B. (2024) · Advanced Science · doi:10.1002/advs.202410416 · Cited by 121
Khalili‐Tanha, G., Radisky, E. S., Radisky, D. C., & Shoari, A. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06447-w · Cited by 112
“A comparable pathological cycle underlies myocardial fibrosis, where hypertension or ischemic injury triggers ECM deposition by myofibroblasts, often supported by MMP upregulation and endothelial-to-mesenchymal transition [129, 130].”
Clonal haematopoiesis of indeterminate potential predicts incident cardiac arrhythmias
Schuermans, A., Vlasschaert, C., Nauffal, V., Cho, S. M. J., Uddin, M. M., Nakao, T., Niroula, A., Klarqvist, M. D. R., Weeks, L. D., Lin, A. E., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad670 · Cited by 101
Multiscale drug screening for cardiac fibrosis identifies MD2 as a therapeutic target
Zhang, H., Thai, P. N., Shivnaraine, R. V., Ren, L., Wu, X., Siepe, D. H., Liu, Y., Tu, C., Shin, H. S., Caudal, A., et al. (2024) · Cell · doi:10.1016/j.cell.2024.09.034 · Cited by 102
Ischemic cardiomyopathy: epidemiology, pathophysiology, outcomes, and therapeutic options
Pastena, P., Frye, J. T., Ho, C., Goldschmidt, M., & Kalogeropoulos, A. P. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10377-4 · Cited by 105
“A sudden surge in cell death stimulates the activation of myofibroblasts and deposits collagen and fibrotic tissue to prevent rupture of the already thin ventricular walls [31].”
Patrick, R., Janbandhu, V. C., Tallapragada, V. J., Tan, S. S. M., McKinna, E. E., Contreras, O., Ghazanfar, S., Humphreys, D. T., Murray, N. J., Tran, T. H. Y., et al. (2024) · Science Advances · doi:10.1126/sciadv.adk8501 · Cited by 99
Li, W., Lou, X., Zha, Y., Qin, Y., Zha, J., Hong, L., Xie, Z., Yang, S.-D., Wang, C., An, J., et al. (2023) · eLife · doi:10.7554/elife.80479 · Cited by 101
Single-cell transcriptome atlas of the human corpus cavernosum
Zhao, L., Han, S., Su, H., Li, J., Zhi, E., Li, P., Yao, C., Tian, R., Chen, H., Chen, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31950-9 · Cited by 99
Pan, K., Hsu, Y., Chang, S., Chung, C., & Lin, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108604 · Cited by 90
“While apoptosis of cardiomyocytes is a contributing factor, progressive myocardial interstitial fibrosis also increases myocardial stiffness and reduces ventricular compliance, which may play a vital role in the development of LV diastolic dysfunction and the pathogenesis of DM cardiomyopathy with preserved LV ejectio…”
BackgroundSun, M., Mao, S., Wu, C., Zhao, X., Guo, C., Hu, J., Xu, S., Zheng, F., Zhu, G., Tao, H., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.065390 · Cited by 88
Myocardial Fibrosis in Hypertrophic Cardiomyopathy: A Perspective from Fibroblasts
Schlittler, M., Pramstaller, P. P., Rossini, A., & Bortoli, M. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914845 · Cited by 86
“The activation of MyoFB can be triggered by several different stimuli, including growth factors, cytokines, mechanical stress, and neurohumoral pathways, such as reninangiotensin-aldosterone signalling or β-adrenergic stimulation [27].”
InfluentialCardiac Fibrosis: Key Role of Integrins in Cardiac Homeostasis and Remodeling
Meagher, P., Lee, X., Lee, J., Visram, A., Friedberg, M. K., & Connelly, K. A. (2021) · Cells · doi:10.3390/cells10040770 · Cited by 81
Selective inhibition of stromal mechanosensing suppresses cardiac fibrosis
Cho, S., Rhee, S., Madl, C. M., Caudal, A., Thomas, D., Kim, H., Kojic, A., Shin, H. S., Mahajan, A., Jahng, J. W. S., et al. (2025) · Nature · doi:10.1038/s41586-025-08945-9 · Cited by 85
“Fibrosis is an integral component of a vast range of cardiac pathological conditions, from inherited cardiomyopathies to ischaemic heart disease 11–13 .”
The spatial and temporal activation of macrophages during fibrosis
Behmoaras, J. V., Mulder, K., Ginhoux, F., & Petretto, E. G. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01186-x · Cited by 86
Liu, Z., Song, K., Tu, B., Lin, L.-C., Sun, H., Zhou, Y., Li, R., Shi, Y., Yang, J., Ye, Z., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102820 · Cited by 82
“It is defined as myocardial interstitial dilation due to deposition of extracellular matrix (ECM) proteins [1].”
BackgroundZhang, N., Ma, Q., You, Y., Xia, X., Xie, C., Huang, Y., Wang, Z., Ye, F., Yu, Z., & Xie, X. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.65802 · Cited by 84
Tu, B., Song, K., Zhou, Y., Sun, H., Liu, Z., Lin, L.-C., Ding, J.-F., Sha, J.-M., Shi, Y., Yang, J., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106840 · Cited by 76
Cardiac System during the Aging Process
Fernandes-Ribeiro, A. S., Zerolo, B. E., López‐Espuela, F., Sanchez, R., & Fernandes, V. S. (2023) · Aging and Disease · doi:10.14336/ad.2023.0115 · Cited by 86
Metabolic and Immune Crosstalk in Cardiovascular Disease
Mohanta, S. K., Heron, C., Klaus‐Bergmann, A., Horstmann, H., Bråkenhielm, E., Giannarelli, C., Habenicht, A. J. R., Gerhardt, H., & Weber, C. (2025) · Circulation Research · doi:10.1161/circresaha.125.325496 · Cited by 77
“74 In response to pathological stimuli, such as angiotensin II, ECs have been observed to upregulate glycolysis and exhibit increased susceptibility to EndMT, leading to fibrosis in specific heart regions.”
Wang, T., Jiang, X., Ruan, Y., Zhuang, J., & Yin, Y. (2022) · Bioengineered · doi:10.1080/21655979.2022.2084253 · Cited by 83
“In certain cardiovascular diseases, an effective strategy to prevent and treat the long-term outcome in patients with ventricular remodeling is to prevent MF [8].”
BackgroundRetractedCentral role of cardiac fibroblasts in myocardial fibrosis of diabetic cardiomyopathy
Cheng, Y., Wang, Y., Yin, R., Xu, Y., Zhang, L., Zhang, Y., Yang, L., & Zhao, D. B. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1162754 · Cited by 75
“A variety of interleukin receptors are expressed in CFs, which regulate the activity of myofibroblasts (10, 22, 180, 181).”
BackgroundCardiac Arrhythmias in Post-COVID Syndrome: Prevalence, Pathology, Diagnosis, and Treatment
Huseynov, A., Akın, İ., Duerschmied, D., & Scharf, R. E. (2023) · Viruses · doi:10.3390/v15020389 · Cited by 75
“Specifically, the cytokine storm, as it may occur typically in response to SARS-CoV-2 infection associated with severe courses, can trigger structural remodeling due to fibrosis pathway activation [48,49].”
BackgroundDirect interrogation of context-dependent GPCR activity with a universal biosensor platform
Janicot, R., Maziarz, M., Park, J., Zhao, J., Luebbers, A., Green, E., Philibert, C. E., Zhang, H., Layne, M. D., Wu, J. C., et al. (2024) · Cell · doi:10.1016/j.cell.2024.01.028 · Cited by 74
Cardiac Remodeling in Heart Failure: Role of Pyroptosis and Its Therapeutic Implications
Chai, R., Xue, W., Shi, S., Zhou, Y., Du, Y., Li, Y., Song, Q., Wu, H., & Hu, Y. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.870924 · Cited by 73
“Role of Pyroptosis in Cardiac Fibrosis Cardiac fibrosis, the expansion of the cardiac interstitium due to a net accumulation of extracellular matrix (ECM) proteins, occurs primarily in cardiac fibroblasts and accompanies most cardiac pathologic conditions (60).”
BackgroundCanty, J. M. (2022) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00093.2022 · Cited by 67
Fibroblast‐mediated intercellular crosstalk in the healthy and diseased heart
Nicin, L., Wagner, J. U. G., Luxán, G., & Dimmeler, S. (2021) · FEBS Letters · doi:10.1002/1873-3468.14234 · Cited by 76
Role of puerarin in pathological cardiac remodeling: A review
Lv, J., Shi, S., Zhang, B., Xu, X., Zheng, H., Li, Y., Cui, X., Wu, H., & Song, Q. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106152 · Cited by 67
Progress and prospect of nanotechnology for cardiac fibrosis treatment
Gaytan, S. L., Beaven, E., Gadad, S. S., & Nurunnabi, M. (2023) · Interdisciplinary medicine · doi:10.1002/inmd.20230018 · Cited by 66
Clinical Significance of MicroRNAs, Long Non-Coding RNAs, and CircRNAs in Cardiovascular Diseases
Singh, D. D., Kim, Y., Choi, S. A., Han, I., & Yadav, D. K. (2023) · Cells · doi:10.3390/cells12121629 · Cited by 65
Trogisch, F. A., Abouissa, A., Keles, M., Birke, A., Fuhrmann, M., Dittrich, G. M., Weinzierl, N., Wink, E., Cordero, J., Elsherbiny, A., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.abq4581 · Cited by 60
“The induction of inflammatory genes [for example, C- X-C motif chemokine ligand 10 ( Cxcl10 ) and galectin 3 ( Lgals3 )] by endothelial SOX9 caused increased recruitment of leukocytes in the heart, which reportedly contribute to tissue fibrosis by releasing paracrine factors (such as TGF-β ) ( 56 ).”
BackgroundCellular crosstalk in fibrosis: Insights into macrophage and fibroblast dynamics
Froom, Z. S. C. S., Callaghan, N. I., & Huyer, L. D. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110203 · Cited by 69
Modeling Heart Diseases on a Chip: Advantages and Future Opportunities
Mourad, O., Yee, R., Li, M., & Nunes, S. S. (2023) · Circulation Research · doi:10.1161/circresaha.122.321670 · Cited by 66
BESSE, S., Nadaud, S., Balse, E., & Pavoine, C. (2022) · Cells · doi:10.3390/cells11071249 · Cited by 74
“However, excessive cardiac fibrosis becomes a key driver of HF, a common pathophysiologic companion of most myocardial diseases, associated with systolic and diastolic dysfunction, aging, arrhythmogenesis, and adverse outcome [212].”
BackgroundInfluentialFibroblasts orchestrate cellular crosstalk in the heart through the ECM
Bowers, S., Meng, Q., & Molkentin, J. D. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-022-00043-7 · Cited by 65
Peikert, A., Fontana, M., Solomon, S. D., & Thum, T. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf524 · Cited by 74
Li, R., & Frangogiannis, N. G. (2022) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2022.07.006 · Cited by 62
Self-citationVendrov, A. E., Han, X., Lozhkin, A. P., Hayami, T., Hu, G., Brody, M. J., Sadoshima, J., Zhang, Y., Runge, M. S., & Madamanchi, N. R. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102937 · Cited by 63
“An increase in macrophage infiltration in the heart results in an inflammatory and pro-fibrotic environment that activates resident cardiac fibroblasts [33].”
BackgroundAAV-mediated YAP expression in cardiac fibroblasts promotes inflammation and increases fibrosis
Francisco, J. J., Zhang, Y., Nakada, Y., Jeong, J. I., Huang, C.-Y., Ivessa, A., Oka, S., Babu, G. J., & Re, D. P. D. (2021) · Scientific Reports · doi:10.1038/s41598-021-89989-5 · Cited by 65
Microvascular Obstruction and Intramyocardial Hemorrhage in Reperfused Myocardial Infarctions
Vora, K. P., Kumar, A., Krishnam, M. S., Prato, F. S., Raman, S. V., & Dharmakumar, R. (2024) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2024.02.003 · Cited by 67
The current landscape of antifibrotic therapy across different organs: A systematic approach
Fuster‐Martínez, I., & Calatayud, S. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107245 · Cited by 63
Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy
Morfino, P., Aimo, A., Castiglione, V., Gálvez‐Montón, C., Emdin, M., & Bayés‐Genís, A. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10279-x · Cited by 72
Engineering cells for therapy and diagnosis
Li, Z., Wang, Y., Gu, Z., & Hu, Q. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00198-x · Cited by 60
“Moreover, CAR-engineered cells are being explored for the treatment of diseases other than cancer, for example cardiac fibrosis 131,132 .”
Ragazzini, S., Scocozza, F., Bernava, G., Auricchio, F., Colombo, G. I., Barbuto, M., Conti, M., Pesce, M., & Garoffolo, G. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.08.063 · Cited by 60
Mitochondrial Calcium Overload Plays a Causal Role in Oxidative Stress in the Failing Heart
Dridi, H., Santulli, G., Bahlouli, L., Miotto, M., Weninger, G., & Marks, A. R. (2023) · Biomolecules · doi:10.3390/biom13091409 · Cited by 66
Varzideh, F., Kansakar, U., Donkor, K., Wilson, S. M., Jankauskas, S. S., Mone, P., Wang, X., Lombardi, A., & Santulli, G. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.863238 · Cited by 59
SGLT1: A Potential Drug Target for Cardiovascular Disease
Zhao, M., Li, N., & Zhou, H. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s418321 · Cited by 62
“Changes in CFs from a resting type to an activated type increase their proliferation and migration capacity and secrete large amounts of extracellular matrix (ECM), contributing to cardiac fibrosis.(94) Under normal conditions, a dynamic balance between ECM catabolism and synthesis is maintained by matrix metalloprote…”
BackgroundNovel Therapies for the Treatment of Cardiac Fibrosis Following Myocardial Infarction
Raziyeva, K., Kim, Y., Zharkinbekov, Z., Temirkhanova, K., & Saparov, A. (2022) · Biomedicines · doi:10.3390/biomedicines10092178 · Cited by 60
“Nevertheless, it should be mentioned that complete inhibition of fibrotic response after MI and other cardiac diseases might have detrimental consequences rather than therapeutic effects due to the fact that fibrosis has important protective effects, namely, it helps maintain the heart’s structural integrity and secur…”
BackgroundMETTL3 boosts glycolysis and cardiac fibroblast proliferation by increasing AR methylation
Zhou, Y., Song, K., Tu, B., Sun, H., Ding, J.-F., Luo, Y., Sha, J.-M., Li, R., Ye, Z., Zhao, J., et al. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.11.042 · Cited by 59
SLC31A1 loss depletes mitochondrial copper and promotes cardiac fibrosis
Tu, B., Song, K., Zhou, Z., Lin, L.-C., Liu, Z., Sun, H., Zhou, Y., Sha, J.-M., Shi, Y., Yang, J., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf130 · Cited by 59
Targeting fibrosis in the failing heart with nanoparticles
Passaro, F., Tocchetti, C. G., Spinetti, G., Paudice, F., Ambrosone, L., Costagliola, C., Cacciatore, F., Abete, P., & Testa, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.004 · Cited by 59
Signaling Pathways and Potential Therapeutic Strategies in Cardiac Fibrosis
Foucault‐Bertaud, A., Joshkon, A., Heim, X., Bachelier, R., Bardin, N., Leroyer, A. S., & Blot‐Chabaud, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021756 · Cited by 56
“Adrenergic stimulation induces cardiac fibroblast proliferation, collagen expression, and the activation of fibroblasts into myofibroblasts mediated by p38MAPK and PI3K [4].”
BackgroundInfluentialWang, L., Feng, J., Xing, F., Meng, D., Zhao, X., Wang, J., Yu, P., Xu, G.-E., Hu, M., Wang, T., et al. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad161 · Cited by 56
Mast cells: a novel therapeutic avenue for cardiovascular diseases?
Poto, R., Marone, G., Galli, S. J., & Varricchi, G. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae066 · Cited by 56
Atrial Cardiomyopathy in Atrial Fibrillation: Mechanistic Pathways and Emerging Treatment Concepts
Karakasis, P., Theofilis, P., Vlachakis, P. K., Ktenopoulos, N., Patoulias, D., Antoniadis, A. P., & Fragakis, N. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14093250 · Cited by 57
“Fibrosis involves more than collagen deposition; it includes proliferation and transdif-ferentiation of mesenchymal cells into α -SMA–positive myofibroblasts and expansion of the ECM with matricellular proteins beyond collagens, such as tenascin-C, biglycan, and thrombospondin-2 [28,138–140].”
Global Research Trends on Ventricular Remodeling: A Bibliometric Analysis From 2012 to 2022
Meng, T., Wang, P., Ding, J., Du, R., Gao, J. X., Li, A., Yu, S., Liu, J., Lu, X., & He, Q. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101332 · Cited by 53
Fibrosis in Pathology of Heart and Kidney: From Deep RNA-Sequencing to Novel Molecular Targets
Schreibing, F., Anslinger, T. M., & Kramann, R. (2023) · Circulation Research · doi:10.1161/circresaha.122.321761 · Cited by 53
Mitochondrial quality control in cardiac fibrosis: Epigenetic mechanisms and therapeutic strategies
Lin, L.-C., Tu, B., Song, K., Liu, Z., Sun, H., Zhou, Y., Sha, J.-M., Yang, J., Ye, Z., Zhao, J., et al. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155626 · Cited by 52
Wang, Y., Wang, J., Liu, C., Li, J., Lu, K., Yu, Q., Zhang, Y., & Shen, Z. (2023) · Journal of Material Science and Technology · doi:10.1016/j.jmst.2023.06.005 · Cited by 51
Takano, M., Kondo, H., Harada, T., Takahashi, M., Ishii, Y., Yamasaki, H., Tong, S., Akiyoshi, K., Shuto, T., Teshima, Y., et al. (2023) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2023.05.007 · Cited by 51
“IL-6 is a proinflammatory cytokine that induces myocardial inflammatory fibrosis and vascular inflammation.(28,29) It also causes excess production of reactive oxygen species like superoxide,(30,31) leading to further exacerbation of inflammation and fibrosis.”
BackgroundLei, Q., Xu, H., Yuan, R., Yun, W., & Ma, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116000 · Cited by 51
Liu, C., Huang, J., Qiu, J., Jiang, H., Liang, S., Su, Y., Lin, J., & Zheng, J. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155467 · Cited by 51
Qu, X., Zhai, B., Hu, W., Lou, M.-H., Chen, Y., Liu, Y., Chen, J., Mei, S., You, Z., Liu, Z., et al. (2022) · European Journal of Nutrition · doi:10.1007/s00394-021-02768-w · Cited by 50
Chen, H., Chew, G., Devapragash, N., Loh, J. Z., Huang, K. Y., Guo, J., Liu, S., Tan, E. L. S., Chen, S., Tee, N., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34971-6 · Cited by 52
“Briefly, pySCENIC (1) derives a set of gene co-expression networks defined by a transcription factor (TF) and its target genes, (2) evaluates a network for enrichment of TF-specific cis-regulatory elements and removes targets genes lacking an enrichment of these elements, and (3) assesses the activity level of the net…”
BackgroundMethodSenescent cardiac fibroblasts: A key role in cardiac fibrosis
Osorio, J. M., Espinoza-Pérez, C., Rimassa-Taré, C., Machuca, V., Bustos, J. O., Vallejos, M., Vargas, H., & Díaz-Araya, G. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166642 · Cited by 53
Fibroblasts and immune cells: at the crossroad of organ inflammation and fibrosis
Smolgovsky, S. A., Theall, B. P., Wagner, N., & Alcaide, P. (2023) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00545.2023 · Cited by 52
Ke, D., Cao, M., Ni, J., Yuan, Y., Deng, J.-Y., Chen, S., Dai, X., & Zhou, H. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05353-x · Cited by 52
Islam, R. M., & Hong, Z. (2024) · Mechanobiology in Medicine · doi:10.1016/j.mbm.2024.100085 · Cited by 50
An antioxidant nanozyme for targeted cardiac fibrosis therapy post myocardial infarction
Gu, Z., Liu, X., Qi, Z., Zhou, F., Jiang, Y., Huang, Y.-T., Wang, Y., Wu, L., & Yang, Y. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-03047-6 · Cited by 54
“In addition, ROS production also exacerbates fibrosis by stimulating TGF-β production, setting off a pro-fibrosis signaling cascade [4, 20].”
Metadata
- Authors
- Frangogiannis, N. G.
- Affiliations
- Albert Einstein College of Medicine (US)
- Corresponding author
- Frangogiannis, Nikolaos G
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-11-02
- Volume
- 117
- Issue
- 6
- Pages
- 1450-1488
- ISSN
- 0008-6363 (ISSN-L)
- 1755-3245
- PMC
- PMC8152700
- OpenAlex
- W4210607007
- Cited by
- 1,229
- References
- 615
- Citations by year
- 2026: 265 · 2025: 319 · 2024: 273 · 2023: 210 · 2022: 130 · 2021: 32
- FWCI
- 15.82
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Cardiovascular Research (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- NIH (R01 HL76246, R01 HL85440, R01 HL149407)
- U.S. Department of Defense (PR151134, PR151029, PR181464)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- myocardial fibrosis, myocardial fibroblasts, myofibroblasts, extracellular matrix deposition, TGF-beta, platelet-derived growth factor, cytokines, mechanoreceptors, integrins, pressure overload, myocardial infarction, heart failure, familial cardiomyopathy, diabetic cardiomyopathy, cardiac arrhythmias
- MeSH terms
- Antifibrotic Agents, Animals, Extracellular Matrix, Fibroblasts, Fibrosis, Humans, Cardiomyopathies, Myocytes, Cardiac, Mechanotransduction, Cellular
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.